German blue chips have been popular with investors this year. Since the start of 2025, the Dax has risen by more than 20% (total return, as of May 22, 2025) and has closed above 24,000 points for the first time ever this week. The MDax, which comprises medium-sized German companies, is also up by more than 17%.
However, a long-term comparison reveals significant performance differences between the two indices. While the Dax is currently reaching record highs and is now trading at more than double the level seen five years ago (+116.7%), the MDax has only gained around 22% in five years.
Although mid-sized stocks are catching up, the performance difference between individual MDax members since the beginning of 2025 is considerable. The index is topped by defence stocks and shares in the steel group Thyssenkrupp, which have risen by more than 100% year-to-date. In contrast, the shares of sportswear manufacturer Puma (-49.8%) and drugstore chain Douglas (-42.3%) have fallen significantly.
Between these extremes we find luxury fashion brand Hugo Boss (-8.6%), sports car manufacturer Porsche (+2.8%) and pharmaceutical and laboratory equipment supplier Sartorius (+4.4%). Zürcher Kantonalbank Research currently rates all three stocks as "Overweight", yet their performance year-to-date has been subdued.
Barrier Reverse Convertible on German Mid Caps
11.80% p.a. BRC on Hugo Boss, Porsche and Sartorius
Barrier: 54%
Valor: 144 651 032
Indicative terms
Disclaimer
This communication is for marketing purposes. It is neither an offer nor an invitation to submit an offer, to purchase or to subscribe to securities and does not constitute investment advice. You should consult your advisors before making an investment decision. Forward-looking statements are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, financial condition, development or performance of the issuer to be materially different from any future results, financial condition, development or performance expressed or implied by such statements. The present document has not been drawn up by the research department as defined in the rules of the “Directives on the Independence of Financial Research” published by the Swiss Bankers Association, hence these rules do not apply to this document. If securities are mentioned in the communication, the base prospectus, the final terms and any key information document may be obtained free of charge from Zürcher Kantonalbank, Bahnhofstrasse 9, 8001 Zurich, VRIS, and from www.zkb.ch/finanzinformationen.
© 2025 Zürcher Kantonalbank. All rights reserved.
ZKB Tracker-Zertifikat Dynamisch auf Quantum Computing 121826631 / CH1218266315 |
ZKB Reverse Convertible auf Unitedhealth Group Inc 142529913 / CH1425299133 |
ZKB Callable Barrier Reverse Convertible on worst of Eli Lilly & Co/Johnson & Johnson/Merck ... 139433613 / CH1394336130 |
6% p.a. ZKB Callable Barrier Reverse Convertible, 14.04.2026 on worst of BARN SE/ROG SE/GALE SE/KNIN... 134140826 / CH1341408263 |
ZKB Callable Barrier Reverse Convertible on worst of mobilezone holding ag/Barry Callebaut AG/Bossar... 140250881 / CH1402508811 |